Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

S. Peters*, U. Dafni, M. Boyer, D. De Ruysscher, C. Faivre-Finn, E. Felip, P. Garrido, N. Girard, M. Guckenberger, J. Haanen, C. Le Pechoux, F. Mornex, M. Ozsahin, L. Paz-Ares, D. Planchard, D. Raben, S. Ramalingam, M. Reck, E. Smit, R. StahelA. Stenzinger, C. Swanton, S. Vallone, M. C. Garassino

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)161-165
Number of pages5
JournalAnnals of Oncology
Volume30
Issue number2
DOIs
Publication statusPublished - Feb 2019

Keywords

  • PROGRAMMED DEATH LIGAND-1
  • CLINICAL BENEFIT
  • RADIOTHERAPY
  • EXPRESSION
  • MAGNITUDE
  • PD-L1

Cite this

Peters, S., Dafni, U., Boyer, M., De Ruysscher, D., Faivre-Finn, C., Felip, E., Garrido, P., Girard, N., Guckenberger, M., Haanen, J., Le Pechoux, C., Mornex, F., Ozsahin, M., Paz-Ares, L., Planchard, D., Raben, D., Ramalingam, S., Reck, M., Smit, E., ... Garassino, M. C. (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2), 161-165. https://doi.org/10.1093/annonc/mdy553